Back to Journals » Drug Design, Development and Therapy » Volume 13

A new approach of ocular nebulization with vitamin B12 versus oxytocin for the treatment of dry eye disease: an in vivo confocal microscopy study

Authors Yang J, Liu Y, Xu Y, Li X, Fu J, Jiang X, Chou Y, Ma J, Hao R, Zhang R, Qiu W, Li X

Received 30 January 2019

Accepted for publication 6 May 2019

Published 18 July 2019 Volume 2019:13 Pages 2381—2391


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng

Jiarui Yang,1,* Yushi Liu,1,* Yanhui Xu,1,* Xiaodan Li,1,* Jiayu Fu,1 Xiaodan Jiang,1 Yilin Chou,1 Jiahui Ma,1 Ran Hao,1 Rong Zhang,2 Weiqiang Qiu,1 Xuemin Li1

1Department of Ophthalmology, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Neurobiology, Health Science Center, School of Basic Medical Sciences, Peking University, Beijing, People’s Republic of China

*These authors contributed equally to this work

Purpose: To present a new ocular nebulization therapy for the treatment of dry eye disease (DED) and investigate the efficacy of vitamin B12 (VB12) and oxytocin (OXT) nebulization with clinical parameters and in vivo confocal microscopy (IVCM).
Patients and methods: Thirty-eight patients with DED were enrolled, with 19 receiving VB12 nebulization and 19 receiving OXT nebulization twice weekly for 3 months. Clinical signs and symptoms including Ocular Surface Disease Index, self-assessment of light sensitivity and dryness, tear meniscus height, tear break-up time (BUT), and corneal staining, along with IVCM data of basal epithelial cell density, sub-basal dendritic cell (DC) density, nerve density, and nerve tortuosity were acquired at baseline, 1 month, and 3 months after starting treatment.
Results: Patients treated with VB12 improved significantly in all signs and symptoms except for nerve tortuosity during the three-month treatment, while OXT demonstrated similar effects apart from BUT and nerve tortuosity. VB12 group revealed a higher BUT at 1 month and 3 months with a higher basal epithelial cell density at 3 months compared with OXT group, and a lower DC density was observed in OXT group at 1 month. Change of basal epithelial cell density was more significant at 3 months in VB12 group, with OXT group showing a significantly higher DC reduction at 1 month.
Conclusion: The nebulization therapy delivering VB12 and OXT appears to be effective in improving the symptoms and signs of dry eye, with a relatively stronger effect of BUT elevation and epithelial repair in VB12 and anti-inflammation in OXT nebulization.

Keywords: dry eye, in vivo confocal microscopy, nebulization, oxytocin, vitamin B12

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]